Previous 10 | Next 10 |
2023-05-11 16:50:41 ET Shares of Guardant Health (NASDAQ: GH) were up 14.8% for the week as of Thursday afternoon and rose as much as 19.8% for the week, according to data provided by S&P Global Market Intelligence . The healthcare stock, which focuses on oncology diagno...
2023-05-10 13:06:47 ET Guardant Health ( NASDAQ: GH ) stock rose ~11% on Wednesday after Q1 results beat estimates and the company raised its FY23 revenue outlook. Non-GAAP net loss per share was -$1.06, compared to -$0.91 in Q1 2022. Total revenue grew +34% Y/Y to $128....
2023-05-10 10:00:34 ET Gainers: CTI BioPharma ( CTIC ) +85% . Cano Health ( CANO ) +29% . TScan Therapeutics ( TCRX ) +24% . RxSight ( RXST ) +11% . Guardant Health ( GH ) +14% . Losers: Babylon Holdings ( BBLN ) -71...
2023-05-10 03:46:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. Baron Global Advantage Fund gained 9.4% in the first quarter of 2023, which compares t...
2023-05-09 23:38:08 ET Guardant Health, Inc. (GH) Q1 2023 Earnings Conference Call May 09, 2023 04:30 PM ET Company Participants Alex Kleban - Vice President-Investor Relations Helmy Eltoukhy - Chairman & Co-Chief Executive Officer AmirAli Talasaz - Co-Chief ...
Not intended for distribution to U.S. newswire services or for dissemination in the U.S. RED DEER, AB / ACCESSWIRE / May 9, 2023 / Gamehost Inc. (TSX:GH) Management and Directors of Gamehost Inc. (the "Company") present results for the three months ended March 31, 2023 (the "Quarter"). The...
2023-05-09 16:38:37 ET Guardant Health press release ( NASDAQ: GH ): Q1 Non-GAAP EPS of -$1.06 beats by $0.01 . Revenue of $128.7M (+33.9% Y/Y) beats by $10.96M . Now expects full year 2023 revenue to be in the range of $535 million to $545 million. G...
Q 1 revenue increased 34% year over year driven by clinical volume growth of 45% Raises 2023 revenue guidance to $535 to $545 million Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally throu...
Shi eld ™ blood test achieved overall 83% sensitivity and 90% specificity and demonstrated early-stage detection in range with other guideline-recommended non-invasive CRC screening modalities Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, t...
Ines Dahne-Steuber named as chief operating officer Darya Chudova promoted to chief technology officer Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the expansion of its leadership team with the addition of Ines Dahne-Steuber as chief ...
News, Short Squeeze, Breakout and More Instantly...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...
2024-07-21 23:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...